Interferon Beta – Medication Which Started the Revolution in the Treatment of Multiple Sclerosis

Jovana Ivanovic; Tatjana Pekmezović; Jelena Drulović

doi:10.5937/mp70-18871

Jovana Ivanovic Medicinski fakultet Univerziteta u Beogradu
Tatjana Pekmezović Institute of Epidemiology Faculty of Medicine, Faculty of Medicine University of Belgrade
Jelena Drulović Clinic of Neurology Clinical Center of Serbia, Faculty of Medicine University of Belgrade

DOI: https://doi.org/10.5937/mp70-18871

Sažetak

Multiple sclerosis is a chronic, inflammatory, demyelinating and neurodegenerative disease of the central nervous system. The etiology is unknown, and it is estimated that about 2.5 million people all around the world are suffering from this disease. It is the most common cause of non-traumatic disability in young adults. The clinical presentation is very variable and unpredictable. There are three basic forms of the disease – relapsing remitting, primary progressive and secondary progressive multiple sclerosis. The prognosis for these patients has changed since 1993, when the first disease modifying therapy – interferon beta, was approved. Interferon beta reduces the number of relapses, reduces the number of hyper intense lesions on T2 sequences of endocranial MRI, mildly delaying the progression of the disease. Interferon beta is also used in pediatric population. It is considered to be generally safe, since it does not increase the likelihood of developing malignancy and opportunistic infections.

Reference

Charcot JM. Disseminated sclerosis: its symptomatology. Lectures on the disease of the nervous system. New Sydenham Society, London, 1877; 209–217.

Duddy M. Epidemiology in multiple sclerosis has had its day: there are no more unanswered questions – Yes. Mult Scler 2012; 18:140-141.

Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted Country, Minnesota, 1985-2000. Neurology Psychiatr 2013; 84:141-7.

Аscherio A, Munger K. Environmental Risk Factors for Multiple Sclerosis. Part II: Noninfectious factors. Ann Neurol 2007; 61:504-13.

Pekmezovic T, Jarebinski M, Drulovic J, Stojsavljevic N, Levic Z. Survival of multiple sclerosis patients in the Belgrade population. Neuroepidemiology 2002; 21:235-40.

Drulović J, Mostarica Stojković M, Pekmezović T,Pravica V, Filipović S, Kisić Tepavčević D, et al. (2013). Multipla skleroza. Beograd: Medicinski fakultet u Beogradu.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58:840-6.

Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81:1039-43.

Dujmovic I, Mesaros S, Pekmezovic T, Levic Z, Drulovic J. Primary progressive multiple sclerosis: clinical and paraclinical characteristics with application of the new diagnostic criteria. Eur J Neurol 2004; 11:439-44.

Thompson A, Banwell B, Barkhof F, Carroll W, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2017; 162-173.

Dackovic J, Stojsavljevic N. Simptomi i znaci multiple skleroze. U: Acta Clinica: Multipla skleroza 2011; 11:61-72.

Duddy M, Haghikia A, Cocco E, Eggers C, Dulovic J, Carmona O, et al. Managing MS in a changing treatment landscape. J Neurol 2011; 258:728-39.

Fox RJ, Kinkel RP. High dose of methylprednisolone in the treatment of multiple sclerosis. In: Cohen JA, Rudick RA, eds. Multiple Sclerosis Therapeutics, London: Informa Healthcare, 3rd Edition; 2007: 515-33.

Frohman TC, Castro W, Shah A, Courtney A, Ortstadt J, Davis SL, et al. Symptomatic therapy in multiple sclerosis. Ther Adv Neurol Disord 2011; 4:83-98.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018; 24(2): 96-120.

Wingerchuk D, Weinshenker B. Disease modifying therapies for relapsing multiple sclerosis. BMJ 2016; 354:i3518.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017; 376(3):221-234.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017; 376 209-220.

Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018; 1-6.

Biogen, 2018. Biogen and AbbVie announce the voluntary world wide withdrawal of marketing authorizations for Zinbryta® (daclizumab) for relapsing multiple sclerosis [online]. Available: http://media.biogen.com/press-release/autoimmune-diseases/biogen%C2%A0and-abbvie-announce%C2%A0-voluntary%C2%A0worldwide-withdrawal-marketi [Accessed 5 March 2018].

Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011;25(6):491-502.

Jacobs L, O’Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214: 1026-1028.

Knobler RL, Panitch HS, BrahenySL,Sipe JC, Rice GP, Huddlestone JR, et al. Systemic alpha-interferon therapy of multiple sclerosis. Neurology 1984;34:1273-1279.

The IFN B Multiple Sclerosis Study Group. Interferon beta lb is effective in relapsing remitting multiple sclerosis: Clinical results of a multicenter randomized double blind, placebo-controlled trial. Neurology 1993; 43:655-661.

Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993; 13(5):333-40.

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285–94.

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45:1277–85.

Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444–52.

Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. AnnNeurol 2007; 61:300–6.

Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308:247–56.

Bergamaschi R, Quaglini S, Tavazzi E, Amato MP, Paolicelli D, Zipoli V, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Multiple Sclerosis 2016 Nov; 22(13):1732-1740.

Drulović J, Kostić J, Mesaroš Š, Dujmović Bašuroski I, Stojsavljević N, Kisić-Tepavčević D, Pekmezović T. Interferone-beta and disability progression in relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg 2013; 115: 65-69.

Gärtner J, Brück W, Weddige A, Hummel H, Norenberg C, Bugge JP. Interferon beta-1b in treatment-naïve paediatric patients with relapsing-remitting multiple sclerosis: Two-year results from the BETAPAEDIC study. Mult Scler J Exp Transl Clin 2017; 3(4):1-9.

Comi G, De Stefano N, Freedman MS, Barkof F, Uitdehaag BM, de Vos M, et al. Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing. Frequency-blind multicentre REFLEXION study. J Neurol Neurosurg Psychiatry 2017; 88(4):285-294.

European Study Group on Interferon-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352(9139):1491-1497.

The North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63(10):1788-1795.

Rojas JI, Romano M, Ciapponi A, Patruccio L, Cristiano E. Interferon Beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev. 2010; 20:(1).

Bayas A, Ouallet JC, Kallmann B, Hupperts R, Fulda U, Marhardt K; SMART study group. Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv 2015; 12(8): 1239-1250.

Hupperts R, Becker V, Friedrich J, Gobbi C, Salgado AV, Sperling B et al. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin Drug Deliv 2015; 12(1):15-25.